Product image of Leflunomida Stada (Leflunomide) supplied by GNH India

Leflunomida Stada

Active Ingredient:
Leflunomide
Origin:
EU

Leflunomida Stada (Leflunomide)

Leflunomide, the active ingredient in Leflunomida Stada, is a disease-modifying antirheumatic drug (DMARD) presented as an oral formulation for systemic use. It is employed to manage rheumatoid arthritis and psoriatic arthritis in adult patients, reducing disease activity and slowing joint damage.

GNH India supplies Leflunomida Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global network ensures timely delivery and compliance with local regulatory requirements.

Manufacturer / TM Owner

Laboratorio Stada, S.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Leflunomide, a disease-modifying antirheumatic drug (DMARD), is used to treat inflammatory joint disorders.

  • Rheumatoid arthritis: reduces joint inflammation, pain, and structural damage, improving functional ability in adult patients.
  • Psoriatic arthritis: alleviates joint swelling and skin lesions, slowing disease progression and enhancing quality of life.
  • Moderate to severe rheumatoid arthritis in patients with inadequate response to conventional DMARDs: offers an alternative therapeutic option to control disease activity.
  • Adult patients with active rheumatoid arthritis requiring long‑term disease control: helps maintain remission and prevent radiographic progression.

How It Works

  • Leflunomide is metabolized to its active form, teriflunomide, which selectively inhibits the mitochondrial enzyme dihydroorotate dehydrogenase. This blockade reduces de novo pyrimidine synthesis, limiting proliferation of activated lymphocytes and thereby diminishing the autoimmune inflammatory response characteristic of rheumatoid and psoriatic arthritis.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Diarrhoea: mild to moderate gastrointestinal upset.
  • Nausea: occasional feeling of queasiness.
  • Alopecia: reversible hair thinning.
  • Elevated liver enzymes: mild transaminase increase.
  • Hypertension: modest rise in blood pressure.
  • Rash: non‑specific skin eruption.

Serious or Rare Side Effects

  • Hepatotoxicity: severe liver injury or failure.
  • Severe infections: opportunistic or bacterial infections requiring medical attention.
  • Pulmonary toxicity: interstitial lung disease or pneumonitis.
  • Bone marrow suppression: neutropenia or anemia.
  • Stevens‑Johnson syndrome: severe skin and mucosal reaction.
  • Teratogenicity: potential fetal harm if exposure occurs during pregnancy.

Precautions & Warnings

Patients should be monitored and counseled before and during therapy.

  • Liver monitoring: perform baseline and periodic liver function tests.
  • Blood pressure: check regularly and manage hypertension if present.
  • Pregnancy: avoid use during pregnancy and discontinue if pregnancy is confirmed.
  • Infection risk: assess for active infections before initiating treatment.
  • Hematology: monitor complete blood count for signs of bone‑marrow suppression.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Leflunomide may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Methotrexate: increased risk of hepatotoxicity and bone‑marrow suppression.
  • Warfarin: enhanced anticoagulant effect, raising bleeding risk.
  • Live vaccines: heightened chance of infection; avoid concurrent administration.

Moderate Interactions (Monitor Closely)

  • Statins: possible increased risk of myopathy.
  • Azathioprine: additive bone‑marrow suppression.
  • Oral contraceptives: reduced efficacy, consider alternative contraception.

Frequently Asked Questions

Leflunomida Stada contains leflunomide, which is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients. It helps reduce joint inflammation, pain, and structural damage, thereby improving functional ability and quality of life.

Leflunomide is converted to its active metabolite teriflunomide, which inhibits the enzyme dihydroorotate dehydrogenase. This blocks pyrimidine synthesis, limiting the proliferation of activated lymphocytes and dampening the autoimmune inflammatory response that drives joint damage in arthritis.

The dosage of Leflunomida Stada is individualized by the prescribing healthcare professional based on the patient’s clinical condition, response, and laboratory monitoring. The prescriber determines the appropriate starting dose, any titration steps, and the maintenance regimen.

Leflunomide is classified as contraindicated in pregnancy because of known teratogenic risk. Women of child‑bearing potential should use effective contraception before, during, and for a defined period after stopping therapy. Breastfeeding is not recommended while taking leflunomide.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Leflunomida Stada. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both leflunomide and methotrexate are conventional DMARDs used for rheumatoid arthritis. Leflunomide has a distinct mechanism—blocking pyrimidine synthesis—while methotrexate inhibits folate metabolism. Clinical choice depends on efficacy, tolerability, patient comorbidities, and physician experience; some patients may respond better to one or require combination therapy.

Store Leflunomida Stada at temperatures below 25 °C, in the original packaging, and protect it from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Leflunomida Stada is taken orally, usually as a tablet, with a glass of water. The medication may be taken with or without food, as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional.

Serious risks include hepatotoxicity, severe infections, pulmonary toxicity, bone‑marrow suppression, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Regular monitoring of liver enzymes, blood counts and respiratory status is essential to detect these events early.

Leflunomida Stada should be avoided in patients with severe liver impairment, active serious infections, known hypersensitivity to leflunomide or its metabolites, and in women who are pregnant or planning pregnancy without effective contraception. Caution is also advised for those with uncontrolled hypertension.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Leflunomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT